Posted: 06 Feb 2020 06:11 PM PST
By Kurt R. Karst —
Hyman, Phelps & McNamara, P.C. is pleased to announce that Sara Koblitz will be speaking in an upcoming Strafford live webinar, “Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation” scheduled for Thursday, February 13, 1:00pm-2:30pm EST. The panel will provide essential updates on FDA practice and patent law relating to biologics and biosimilars and discuss the current state of and recent changes to FDA initiatives, approvals, and exclusivities, as well as patent prosecution, post-grant proceedings, and litigation.
After the presentations, the speakers will engage in a live question and answer session with participants, so they can answer your questions about these issues directly.
As readers of our blog, you can participate in this program at half off. Use this link, and the offer will be reflected automatically in your cart. Alternatively, you can call 1-800-926-7926. Ask for Biologics and Biosimilars: FDA Initiatives and Guidance on 2/13/2020, and mention code: ZDFCA.
Hyman, Phelps & McNamara, P.C. is pleased to announce that Sara Koblitz will be speaking in an upcoming Strafford live webinar, “Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation” scheduled for Thursday, February 13, 1:00pm-2:30pm EST. The panel will provide essential updates on FDA practice and patent law relating to biologics and biosimilars and discuss the current state of and recent changes to FDA initiatives, approvals, and exclusivities, as well as patent prosecution, post-grant proceedings, and litigation.
After the presentations, the speakers will engage in a live question and answer session with participants, so they can answer your questions about these issues directly.
As readers of our blog, you can participate in this program at half off. Use this link, and the offer will be reflected automatically in your cart. Alternatively, you can call 1-800-926-7926. Ask for Biologics and Biosimilars: FDA Initiatives and Guidance on 2/13/2020, and mention code: ZDFCA.
.png)
No hay comentarios:
Publicar un comentario